Cargando…

Bone lead, hypertension, and lead nephropathy.

There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may ref...

Descripción completa

Detalles Bibliográficos
Autor principal: Wedeen, R P
Formato: Texto
Lenguaje:English
Publicado: 1988
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474623/
https://www.ncbi.nlm.nih.gov/pubmed/3203647
_version_ 1782127949861879808
author Wedeen, R P
author_facet Wedeen, R P
author_sort Wedeen, R P
collection PubMed
description There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 micrograms/g wet weight) and approximated levels found in lead workers (30 micrograms/g). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies.
format Text
id pubmed-1474623
institution National Center for Biotechnology Information
language English
publishDate 1988
record_format MEDLINE/PubMed
spelling pubmed-14746232006-06-09 Bone lead, hypertension, and lead nephropathy. Wedeen, R P Environ Health Perspect Research Article There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6 micrograms/g wet weight) and approximated levels found in lead workers (30 micrograms/g). At present, the most reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead, which should find widespread application as a diagnostic tool and for epidemiologic studies. 1988-06 /pmc/articles/PMC1474623/ /pubmed/3203647 Text en
spellingShingle Research Article
Wedeen, R P
Bone lead, hypertension, and lead nephropathy.
title Bone lead, hypertension, and lead nephropathy.
title_full Bone lead, hypertension, and lead nephropathy.
title_fullStr Bone lead, hypertension, and lead nephropathy.
title_full_unstemmed Bone lead, hypertension, and lead nephropathy.
title_short Bone lead, hypertension, and lead nephropathy.
title_sort bone lead, hypertension, and lead nephropathy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474623/
https://www.ncbi.nlm.nih.gov/pubmed/3203647
work_keys_str_mv AT wedeenrp boneleadhypertensionandleadnephropathy